Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
Ludwig Kappos(University Hospital of Basel), Stephen L. Hauser(University of California, San Francisco), Peter A. Calabresi(Johns Hopkins University), Frederik Barkhof(National Hospital for Neurology and Neurosurgery), Ming Yin(Brigham and Women's Hospital), Amit Bar‐Or(University of Pennsylvania), Robert Glanzman(Roche (Switzerland)), David Li(University of Alberta), Paul O’Connor(Augusta University), David Leppert, Jeroen Tinbergen(Roche (Switzerland))
Cited by 743
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k